Case study

European Asset Due Diligence

Bringing European markets’ price, access and reimbursement insight to support global in-licensing decisions


A major global pharma company was considering therapy area expansion through in-licensing

The global Business Development team recognised the need for European HTA, price & reimbursement insights but the in-house European market access team lacked bandwidth to respond quickly


AESARA deployed a team of industry-veteran strategy consultants and payer researchers to:

  • Execute a 4-week project, combining secondary and primary research with experience-based AESARA analysis,
  • Quickly and succinctly assess the European value & access opportunity for the asset
  • Test product value and price assumptions via double-blind interviews with European HCPs and payers/HTA advisors
  • Identify the BD&L implications for client decision-makers

Market Access Consulting

  • Enabling Activity
    Training development & delivery
  • Region
  • Client
    Global Head of HEOR


A timely, clear and well-presented report covering,
for priority European markets:

  • Market size/opportunity
  • HTA insights
  • TPP value
  • Price potential

Enabled executive decision on go/no-go for the opportunity

Contact us

Fill out the form below, and we will be in touch shortly.